Literature DB >> 1303629

Birth prevalence study of the Apert syndrome.

M M Cohen1, S Kreiborg, E J Lammer, J F Cordero, P Mastroiacovo, J D Erickson, P Roeper, M L Martínez-Frías.   

Abstract

Estimates of the Apert syndrome birth prevalence and the mutation rate are reported for Washington State, Nebraska, Denmark, Italy, Spain, Atlanta, and Northern California. Data were pooled to increase the number of Apert births (n = 57) and produce a more stable birth prevalence estimate. Birth prevalence of the Apert syndrome was calculated to be approximately 15.5/1,000,000 births, which is twice the rate determined in earlier studies. The major reason appears to be incomplete ascertainment in the earlier studies. The similarity of the point estimates and the narrow bounds of the confidence limits in the present study suggest that the birth prevalence of the Apert syndrome over different populations is fairly uniform. The mutation rate was calculated to be 7.8 x 10(-6) per gene per generation. Apert syndrome accounts for about 4.5% of all cases of craniosynostosis. The mortality rate appears to be increased compared to that experienced in the general population; however, further study of the problem is necessary.

Entities:  

Mesh:

Year:  1992        PMID: 1303629     DOI: 10.1002/ajmg.1320420505

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  47 in total

1.  DNA enrichment by allele-specific hybridization (DEASH): a novel method for haplotyping and for detecting low-frequency base substitutional variants and recombinant DNA molecules.

Authors:  Alec J Jeffreys; Celia A May
Journal:  Genome Res       Date:  2003-10       Impact factor: 9.043

2.  Differential effects of FGFR2 mutations on syndactyly and cleft palate in Apert syndrome.

Authors:  S F Slaney; M Oldridge; J A Hurst; G M Moriss-Kay; C M Hall; M D Poole; A O Wilkie
Journal:  Am J Hum Genet       Date:  1996-05       Impact factor: 11.025

3.  Sleep-disordered breathing in children with craniosynostosis.

Authors:  Muslim M Alsaadi; Shaikh M Iqbal; Essam A Elgamal; Mustafa A Salih; David Gozal
Journal:  Sleep Breath       Date:  2012-04-26       Impact factor: 2.816

4.  A germ-line-selective advantage rather than an increased mutation rate can explain some unexpectedly common human disease mutations.

Authors:  Soo-Kyung Choi; Song-Ro Yoon; Peter Calabrese; Norman Arnheim
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-16       Impact factor: 11.205

5.  Comparison of ultrasound and magnetic resonance imaging in the prenatal diagnosis of Apert syndrome: report of a case.

Authors:  A Giancotti; V D'Ambrosio; A De Filippis; C Aliberti; G Pasquali; S Bernardo; L Manganaro
Journal:  Childs Nerv Syst       Date:  2014-02-25       Impact factor: 1.475

Review 6.  The molecular and cellular basis of Apert syndrome.

Authors:  Chao Liu; Yazhou Cui; Jing Luan; Xiaoyan Zhou; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2013-11

7.  Apert syndrome without craniosynostosis.

Authors:  Diego de Ângelis Ramos; Hamilton Matushita; Daniel Dante Cardeal; Clarissa Nóbrega Gambarra Nascimento; Manoel Jacobsen Teixeira
Journal:  Childs Nerv Syst       Date:  2019-01-14       Impact factor: 1.475

8.  Postnatal brain and skull growth in an Apert syndrome mouse model.

Authors:  Cheryl A Hill; Neus Martínez-Abadías; Susan M Motch; Jordan R Austin; Yingli Wang; Ethylin Wang Jabs; Joan T Richtsmeier; Kristina Aldridge
Journal:  Am J Med Genet A       Date:  2013-03-12       Impact factor: 2.802

9.  Paternal origin of FGFR3 mutations in Muenke-type craniosynostosis.

Authors:  Sahan V Rannan-Eliya; Indira B Taylor; I Marieke De Heer; Ans M W Van Den Ouweland; Steven A Wall; Andrew O M Wilkie
Journal:  Hum Genet       Date:  2004-07-07       Impact factor: 4.132

10.  The ups and downs of mutation frequencies during aging can account for the Apert syndrome paternal age effect.

Authors:  Song-Ro Yoon; Jian Qin; Rivka L Glaser; Ethylin Wang Jabs; Nancy S Wexler; Rebecca Sokol; Norman Arnheim; Peter Calabrese
Journal:  PLoS Genet       Date:  2009-07-10       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.